4.3 Article

Validity of breast cancer surgery treatment information in a state-based cancer registry

期刊

CANCER CAUSES & CONTROL
卷 33, 期 2, 页码 261-269

出版社

SPRINGER
DOI: 10.1007/s10552-021-01520-3

关键词

Breast cancer; Epidemiology; Methods; Cancer registry; Validity

资金

  1. Robert Wood Johnson Foundation Health Policy Research Scholars Award
  2. Agency for Healthcare Research dissertation research award [R36HS027299]
  3. UNC Lineberger Comprehensive Cancer Center, University Cancer Research Fund via the State of North Carolina

向作者/读者索取更多资源

Surgery is a crucial part of early breast cancer treatment, with many studies relying on data sources that under-sample populations affected by care inequities. This study used cancer registry data combined with insurance claims to assess the accuracy of breast cancer surgery treatment information, finding that registry data reliably identified surgery receipt and type, especially in underrepresented populations.
Purpose Surgery is an important part of early stage breast cancer treatment that affects overall survival. Many studies of surgical treatment of breast cancer rely on data sources that condition on continuous insurance coverage or treatment at specified facilities and thus under-sample populations especially affected by cancer care inequities including the uninsured and rural populations. Statewide cancer registries contain data on first course of cancer treatment for all patients diagnosed with cancer but the accuracy of these data are uncertain. Methods Patients diagnosed with stage I-III breast cancer between 2003 and 2016 were identified using the North Carolina Central Cancer Registry and linked to Medicaid, Medicare, and private insurance claims. We calculated the sensitivity, specificity, positive predictive value, negative predictive value, and Kappa statistics for receipt of surgery and type of surgery (breast conserving surgery or mastectomy) using the insurance claims as the presumed gold standard. Analyses were stratified by race, insurance type, and rurality. Results Of 26,819 patients who met eligibility criteria, 23,125 were identified as having surgery in both the claims and registry for a sensitivity of 97.9% (95% CI 97.8%, 98.1%). There was also strong agreement for surgery type between the cancer registry and the insurance claims (Kappa: 0.91). Registry treatment data validity was lower for Medicaid insured patients than for Medicare and commercially insured patients. Conclusions Cancer registry treatment data reliably identified receipt and type of breast cancer surgery. Cancer registries are an important source of data for understanding cancer care in underrepresented populations.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Letter Oncology

Financial Burden of Lymphedema Hospitalizations in the United States

Mya L. Roberson, Paula D. Strassle, Luther-King Okunade Fasehun, Daniel O. Erim, E. Gene Deune, Adeyemi A. Ogunleye

JAMA ONCOLOGY (2021)

Article Dermatology

Performance of ABCD-10 and SCORTEN mortality prediction models in a cohort of patients with Stevens-Johnson syndrome/toxic epidermal necrolysis

Michael J. Duplisea, Mya L. Roberson, Lori Chrisco, Paula D. Strassle, Felicia N. Williams, Carolyn M. Ziemer

Summary: The ABCD-10 model was proposed as an alternative to SCORTEN for predicting in-hospital mortality in patients with SJS/TEN, but in a study at a large tertiary burn center, SCORTEN was found to be a better predictor of inpatient mortality. Both models showed good discrimination, but SCORTEN had better calibration for predicting mortality in this patient cohort.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)

Article Pediatrics

Factors associated with inguinal hernia repair in premature infants during neonatal admission

Adesola C. Akinkuotu, Mya Roberson, Paula D. Strassle, Michael R. Phillips, Sean E. McLean, Andrea Hayes-Jordan

Summary: This study evaluated factors related to early inguinal hernia repair (IHR) in premature infants. The results showed that early IHR was more commonly performed in non-Hispanic White, female neonates, and at urban teaching hospitals. Patient race and hospital type were determinants of early IHR in premature neonates.

JOURNAL OF PEDIATRIC SURGERY (2022)

Article Surgery

Bridging Endocrine Therapy for HR+/HER2-Resectable Breast Cancer: Is it Safe?

Kathleen A. Iles, Madeline Thornton, Jihye Park, Mya Roberson, Philip M. Spanheimer, David W. Ollila, Kristalyn Gallagher

Summary: The study compared treatment methods and outcomes of patients diagnosed with HR+/HER2- breast cancer in 2019 and 2020, finding that more patients in 2020 utilized neoadjuvant endocrine therapy as bridging therapy. The impact on clinical and pathologic staging was similar across different treatment approaches, but neoadjuvant endocrine therapy was shown to optimize healthcare utilization.

AMERICAN SURGEON (2022)

Article Oncology

Trends in surgical treatment of early-stage breast cancer reveal decreasing mastectomy use between 2003 and 2016 by age, race, and rurality

Mya L. Roberson, Hazel B. Nichols, Andrew F. Olshan, Stephanie B. Wheeler, Katherine E. Reeder-Hayes, Whitney R. Robinson

Summary: This study examines trends in surgical treatment of breast cancer in a racially diverse state in the Southeastern US, focusing on age, rurality, and Black women. The results show a decline in mastectomy rates and an increase in breast-conserving surgery rates between 2003 and 2016. These trends were consistent among different age groups, Black women, and women residing in rural areas.

BREAST CANCER RESEARCH AND TREATMENT (2022)

Editorial Material Oncology

Structural Racism and Cancer: Calls to Action for Cancer Researchers to Address Racial/Ethnic Cancer Inequity in the United States

L. Alicia Best, L. Mya Roberson, J. Jesse Plascak, E. Caryn Peterson, R. Charles Rogers, A. Theresa Hastert, Yamile Molina

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2022)

Article Oncology

The impact of age and nodal status on variations in oncotype DX testing and adjuvant treatment

Kathleen Iles, Mya L. Roberson, Philip Spanheimer, Kristalyn Gallagher, David W. Ollila, Paula D. Strassle, Stephanie Downs-Canner

Summary: This analysis examines the use of Oncotype DX (ODX) testing and its association with adjuvant chemotherapy (AC) receipt in breast cancer patients. The study shows that older patients are less likely to receive ODX testing, while nodal positivity increases its use. High ODX recurrence score (RS) is associated with increased mortality, especially among younger node-negative women.

NPJ BREAST CANCER (2022)

Editorial Material Dermatology

JAMA Dermatology's Commitment to Diversity, Equity, and Inclusion

Mya L. Roberson, Adewole S. Adamson, Kanade Shinkai

JAMA DERMATOLOGY (2022)

Letter Oncology

Receipt of Bilateral Mastectomy Among Women With Hereditary Breast Cancer

Sonya Reid, Mya L. Roberson, Kenna Koehler, Tiana Shah, Anne Weidner, Jennifer G. Whisenant, Tuya Pal

Summary: This case series study investigates the differences in surgical treatment between adult females with invasive breast cancer who have pathogenic or likely pathogenic variants in genes with high vs moderate breast cancer penetrance.

JAMA ONCOLOGY (2023)

Editorial Material Oncology

Envisioning trans-inclusive and trans-specific cancer care

Elle Lett, Joannie M. Ivory, Mya L. Roberson

Summary: Transgender patients are marginalized and current oncology standards need improvement. This Comment highlights the need for inclusive and specific practices in cancer care for transgender populations while identifying evidence gaps.

NATURE REVIEWS CLINICAL ONCOLOGY (2023)

Editorial Material Dermatology

Characterizing Epidemiology and Burden of Disease in Alopecia Areata-Making It Count

Amy J. McMichael, Mya L. Roberson

JAMA DERMATOLOGY (2023)

Editorial Material Dermatology

Introducing the JAMA Dermatology Editorial Fellowship

Mya L. Roberson, Kanade Shinkai

JAMA DERMATOLOGY (2023)

Article Health Care Sciences & Services

A Qualitative Study of the Impact of the COVID-19 Pandemic on Metastatic Breast Cancer Care

Joshua Woods, Shekinah N. C. Elmore, Lesley Glenn, Julia Maues, Deltra James, Mya L. Roberson

Summary: The COVID-19 pandemic has had a significant impact on the care of patients with metastatic breast cancer. The study found that there were varying preferences for telehealth, disruptions in care, and a shift towards virtual social care.

JOURNAL OF PATIENT EXPERIENCE (2023)

Letter Health Care Sciences & Services

Evaluating Costs Associated With Genetic Counseling Among Commercially Insured US Patients With Cancer From 2013 to 2019

Mya L. Roberson, Nana Addo Padi-Adjirackor, Gillian Hooker, Tuya Pal

Summary: This study examines the prevalence of out-of-pocket costs for cancer-related genetic counseling services in the United States.

JAMA HEALTH FORUM (2022)

暂无数据